$PMCB UNC Researchers Progress on Cannabis Study to Develop Cancer Treatments http://www.unco.edu/news/releases.aspx?id=10173
Two scientific papers that will be presented this spring detail the progress of cannabis research aimed at developing targeted cancer treatments as part of an ongoing study led by University of Northern Colorado professor Richard Hyslop.
Hyslop and a team of UNC scientists that includes chemistry students are investigating the feasibility of PharmaCyte Biotech Inc.'s patented cell encapsulation technology for treating cancer and diabetes. Initial results suggest that cannabis compounds possess potent anti-proliferative effects against several types of cancer cells. Researchers to date have observed five cell lines that produce desired enyzmes to convert inactive cannabis compounds into anti-cancer drugs once they're injected and then activated directly at the site of a tumor.
The group has submitted proposals to present the papers at the American Chemical Society National Meeting, April 2-6 in San Francisco. The titles of the papers are: "Development of a cannabinoid-based Cell-in-a-Box therapeutic system targeted toward malignant tumors" and "In vitro anti-neoplastic activity of specific phytocannabinoids of Cannabis sativa."
Hyslop has been involved in cancer research for four decades and is leading a team of scientists from UNC to develop a "green" approach to treating solid tumors, initially brain cancer.
"We are looking forward to sharing some of our results with the scientific community," Hyslop said. "Our team of biochemists, organic chemists, molecular biologists, genetic engineers, undergraduate students, and graduate students continue to work diligently to achieve our goal of developing targeted cannabinoid-based chemotherapy utilizing Cell-in-a-Box."
PharmaCyte's chief executive officer Kenneth L. Waggoner added: "We are very pleased with the ongoing progress at UNC. The upcoming ACS meeting provides an ideal venue to present two more scientific papers that have been generated from the work being done by Dr. Hyslop and his students as well as showcase the versatility of Cell-in-a-Box as an advanced therapeutic platform."